Printer Friendly


 COLLEGEVILLE, Pa., and PARIS, Sept. 9 /PRNewswire/ -- Rhone-Poulenc Rorer (NYSE: RPR) announced today senior organizational changes.
 "Since the creation of RPR three years ago, the company has continued to put in place organizational and other changes intended to streamline the structure of our senior executive team," said Robert E. Cawthorn, chairman and chief executive officer. "During the initial period of merging and structuring the new company, the establishment of the Office of the President, presided over by two executive vice presidents of the corporation, was a strategy to ensure continuity and efficient integration of RPR's key businesses and markets. Therefore, it has been our intention for some time to bring greater consolidation to global operations. The organizational changes RPR is implementing today are designed to achieve that unity and to ensure our future growth."
 In light of this strategy, the Board of Directors of RPR has elected Michel de Rosen president and chief operating officer of RPR, reporting to Robert E. Cawthorn, and a member of the board. He takes over the responsibilities of the Office of the President and will be based in Collegeville. This appointment is effective immediately.
 Randy H. Thurman, executive vice president, RPR, and president, RPR Pharmaceuticals Inc. is leaving the company to become chairman and chief executive officer of Corning's laboratory services business (Metpath/Damon Labs) and join the Board of Directors of Corning's pharmaceutical and environmental businesses.
 Jean-Jacques Bertrand, executive vice president, RPR, and president, RPR S.A., will be proposed as vice chairman and chief executive officer of Pasteur Mrieux Serums and Vaccines, to its Board of Directors. He will assume his new responsibilities effective Jan. 1, 1994.
 "I sincerely want to thank Randy Thurman and Jean-Jacques Bertrand for the impressive contributions they have made to RPR," said Robert E. Cawthorn. "Under their leadership, RPR accomplished what many people consider to be the most successful merger in the pharmaceutical industry. Since its creation, RPR's growth has outpaced that of the pharmaceutical industry. The Board of Directors of RPR joins me in wishing them great success in their new positions."
 Michel de Rosen moves to RPR from Rhone-Poulenc where he has served as the chief executive officer of the Fibers and Polymers sector since 1988. He began his professional career as a senior official with the French government. He joined the RP Group in 1982 as the assistant to the president of the Health Sector. Shortly thereafter, he became General Manager of Pharmuka, an RP French pharmaceutical affiliate. From 1986 to 1988, he returned to the French government to become chief of staff for the Minister of Industry.
 "Having known and admired Michel for many years, I am delighted to welcome him to RPR where his wide experience will be a valuable asset," said Robert E. Cawthorn. "In addition to his knowledge of the pharmaceutical industry, his achievements in managing in a highly competitive industry such as fibers, where cost-effectiveness is critical for survival, proves that he possesses the management strengths that are becoming increasingly necessary for success in the pharmaceutical industry. His knowledge of government is also an important asset in our industry which is under increasing government pressure around the world."
 RPR is a global pharmaceutical company dedicated to the discovery, development, manufacture and marketing of human pharmaceuticals. The company reported sales of $4.1 billion and invested over $500 million in research and development in 1992.
 -0- 9/9/93
 /CONTACT: Rhone-Poulenc Rorer media inquiries, 215-454-8035, or investor inquiries, 215-454-3851/

CO: Rhone-Poulenc Rorer ST: Pennsylvania IN: MTC SU: PER

CC -- PH025 -- 0492 09/09/93 17:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1993

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters